Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Treatment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Countries

References

• Chan-Ling T, Gole GA, Quinn GE, Adamson SJ, Darlow BA. Pathophysiology, screening and treatment of ROP: a multi-disciplinary perspective. Prog Retin Eye Res. 2018;62:77–119. doi:10.1016/j.preteyeres.2017.09.002
   PubMed Web of Science ®Google Scholar
• Smith LEH. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res. 2004;14(Suppl A):S140–S144. doi:10.1016/j.ghir.2004.03.030
   PubMedGoogle Scholar
• Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84(2):77–82. doi:10.1016/j.earlhumdev.2007.11.009
   PubMed Web of Science ®Google Scholar
• World Health Organization. Vision 2020: Global Initiative for the Elimination of Avoidable Blindness: Action Plan 2006–2011; 2007. Availbale from: https://apps.who.int/iris/handle/10665/43754. Accessed February 2, 2023.
   Google Scholar
• Borroni C, Carlevaro C, Morzenti S, et al. Survey on retinopathy of prematurity (ROP) in Italy. Ital J Pediatr. 2013;39:43. doi:10.1186/1824-7288-39-43
   PubMed Web of Science ®Google Scholar
• Holmström G, El Azazi M, Jacobson L, Lennerstrand G. A population based, prospective study of the development of ROP in prematurely born children in the Stockholm area of Sweden. Br J Ophthalmol. 1993;77(7):417–423. doi:10.1136/bjo.77.7.417
   PubMed Web of Science ®Google Scholar
• Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013;74(Suppl 1):35–49. doi:10.1038/pr.2013.205
   PubMed Web of Science ®Google Scholar
• Blencowe H, Moxon S, Gilbert C. Update on blindness due to retinopathy of prematurity globally and in India. Indian Pediatr. 2016;53(Suppl 2):S89–S92.
   PubMedGoogle Scholar
• Vinekar A, Azad R, Dogra MR, Narendran V, Jalali S, Bende P. The Indian retinopathy of prematurity society: a baby step towards tackling the retinopathy of prematurity epidemic in India. Ann Eye Sci. 2017;2(27):2–6. doi:10.21037/aes.2017.04
   Google Scholar
• Charan R, Dogra MR, Gupta A, Narang A. The incidence of retinopathy of prematurity in a neonatal care unit. Indian J Ophthalmol. 1995;43:123–126.
   PubMedGoogle Scholar
• Gopal L, Sharma T, Ramachandran S, Shanmugasundaram R, Asha V. Retinopathy of prematurity: a study. Indian J Ophthalmol. 1995;43:59–61.
   PubMedGoogle Scholar
• Ahuja AA, Reddy V, Adenuga OO, et al. Risk factors for retinopathy of prematurity in a district in south India: a prospective cohort study. Oman J Ophthalmol. 2018;11:33–37. doi:10.4103/ojo.OJO_97_2016
   PubMedGoogle Scholar
• Vasavada D, Sengupta S, Prajapati VK, Patel S Incidence and risk factors of retinopathy of prematurity in western India - report from a regional institute of ophthalmology. Nepal J Ophthalmol. 2017;9:112–1120.
   Google Scholar
• Maheshwari R, Kumar H, Paul VK, Singh M, Deorari AK, Tiwari HK. Incidence and risk factors of retinopathy of prematurity in a tertiary care newborn unit in New Delhi. Natl Med J India. 1996;9:211–214.
   PubMed Web of Science ®Google Scholar
• Public Health Foundation in India (PHFI). Project operational guidelines: prevention of blindness from retinopathy of prematurity in neonatal care units; 2019. Available from: https://phfi.org/wp-content/uploads/2019/05/2018-ROP-operational-guidelines.pdf. Accessed February 2, 2023.
   Google Scholar
• Vinekar A, Mangalesh S, Jayadev C, Gilbert C, Dogra M, Shetty B. Impact of expansion of telemedicine screening for retinopathy of prematurity in India. Indian J Ophthalmol. 2017;65(5):390–395. doi:10.4103/ijo.IJO_211_17
   PubMed Web of Science ®Google Scholar
• Parappil H, Pai A, Mahmoud N, AlKhateeb M, Al Rifai H, El Shafei M. Management of retinopathy of prematurity in a neonatal unit: current approach. Wolters Kluwer Medknow Publ. 2019;8(4):203–211. doi:10.4103/jcn.JCN_102_18
   Google Scholar
• National Neonatology Forum, India. Clinical practice guidelines: screening and management of retinopathy of prematurity. National Neonatology Forum; 2020. Availbale from: http://www.nnfi.org/assests/pdf/cpg-guidelines/ropp.pdf. Accessed February 2, 2023.
   Google Scholar
• Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367(26):2515–2526. doi:10.1056/NEJMra1208129
   PubMed Web of Science ®Google Scholar
• Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev. 2018;1:CD009734. doi:10.1002/14651858.CD009734.pub3
   PubMedGoogle Scholar
• Hardy RJ, Good WV, Dobson V, et al. Multicenter trial of early treatment for retinopathy of prematurity: study design. Control Clin Trials. 2004;25(3):311–325. doi:10.1016/j.cct.2004.03.003
   PubMedGoogle Scholar
• Agarwal K, Balakrishnan D, Rani PK, Jalali S. Changing patterns of early childhood blinding conditions presenting to a tertiary eye center: the epidemic of retinopathy of prematurity in India. Indian J Ophthalmol. 2019;67(6):816–818. doi:10.4103/ijo.IJO_709_18
   PubMed Web of Science ®Google Scholar
• Patel SS, Shendurnikar N. Retinopathy of prematurity in India: incidence, risk factors, outcome and the applicability of current screening criteria. Int J Contemp Pediatr. 2019;6(6):2235–2241. doi:10.18203/2349-3291.ijcp20194698
   Google Scholar
• National Health Mission. Resource document: revised guidelines for universal eye screening in newborns including ROP; 2022. Availbale from: https://nhm.gov.in/images/pdf/programmes/RBSK/Resource_Documents/Revised_ROP_Guidelines-Web_Optimized.pdf. Accessed February 2, 2023.
   Google Scholar
• Chiang MF, Quinn GE, Fielder AR, et al. International classification of retinopathy of prematurity, third edition. Ophthalmology. 2021;128(10):e51–e68. doi:10.1016/j.ophtha.2021.05.031
   PubMed Web of Science ®Google Scholar
• Shukla R, Murthy GVS, Gilbert C, Vidyadhar B, Mukpalkar S. Operational guidelines for ROP in India: a summary. Indian J Ophthalmol. 2020;68(Suppl 1):S108–S114. doi:10.4103/ijo.IJO_1827_19
   PubMed Web of Science ®Google Scholar
• Fierson WM, Saunders RA, Good W; American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013;131(1):189–195. doi:10.1542/peds.2012-2996
   PubMed Web of Science ®Google Scholar
• Enríquez AB, Avery RL, Baumal CR. Update on anti-vascular endothelial growth factor safety for retinopathy of prematurity. Asia Pac J Ophthalmol. 2020;9(4):358–368. doi:10.1097/APO.0000000000000302
   PubMed Web of Science ®Google Scholar
• Connolly BP, Ng EYJ, McNamara JA, Regillo CD, Vander JF, Tasman W. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome. Ophthalmology. 2002;109(5):936–941. doi:10.1016/s0161-6420(01)01015-6
   PubMed Web of Science ®Google Scholar
• Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol. 1988;106(4):471–479. PMID: 2895630. doi:10.1001/archopht.1988.01060130517027
   PubMedGoogle Scholar
• Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684–1694. PMID: 14662586. doi:10.1001/archopht.121.12.1684
   PubMedGoogle Scholar
• Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603–615. doi:10.1056/NEJMoa1007374
   PubMed Web of Science ®Google Scholar
• Narnaware SH, Bawankule PK, Raje D. Aggressive Posterior Retinopathy of Prematurity (APROP): LASER as the primary modality of treatment. J Ophthalmic Vis Res. 2021;16(3):400–407. doi:10.18502/jovr.v16i3.9437
   PubMed Web of Science ®Google Scholar
• Singh SR, Katoch D, Handa S, et al. Safety and efficacy of 532 nm frequency-doubled Nd-YAG green laser photocoagulation for treatment of retinopathy of prematurity. Indian J Ophthalmol. 2019;67(6):860–865. doi:10.4103/ijo.IJO_325_19
   PubMedGoogle Scholar
• Chhabra K, Kaur P, Singh K, Aggarwal A, Chalia D. Outcome of solid-state 532 nm green laser in high-risk retinopathy of prematurity at a tertiary care centre in India. Int Ophthalmol. 2018;38(1):287–291. doi:10.1007/s10792-017-0460-3
   PubMed Web of Science ®Google Scholar
• Kara C, Petriçli İS, Hekimoğlu E, Akil H, Beyazyildiz Ö. Treatment success of laser therapy for retinopathy of prematurity in referred and non-referred patients. Arq Bras Oftalmol. 2016;79(2):96–99. doi:10.5935/0004-2749.20160029
   PubMed Web of Science ®Google Scholar
• Vinekar A, Jayadev C, Mangalesh S, et al. Comparing the outcome of single versus multiple session laser photoablation of flat neovascularization in zone 1 aggressive posterior retinopathy of prematurity: a prospective randomized study. Retina. 2015;35(10):2130–2136. doi:10.1097/IAE.0000000000000604
   PubMed Web of Science ®Google Scholar
• Chawla D, Darlow BA. Anti-vascular endothelial growth factor preparations in the treatment of retinopathy of prematurity: balancing risks and benefits. Indian Pediatr. 2016;53(Suppl 2):S129–S136.
   PubMedGoogle Scholar
• Gangwe A, Agrawal D, Vinekar A, Azad RV, Parchand SM, Agrawal D. Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: a survey among the members of Indian retinopathy of prematurity society. Indian J Ophthalmol. 2021;69(8):2158–2163. doi:10.4103/ijo.IJO_200_21
   PubMed Web of Science ®Google Scholar
• Shanmugam PM. Changing paradigms of anti-VEGF in the Indian scenario. Indian J Ophthalmol. 2014;62(1):88–92. doi:10.4103/0301-4738.126189
   PubMed Web of Science ®Google Scholar
• Spandau U. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity? Acta Ophthalmol. 2013;91(2):e154. doi:10.1111/j.1755-3768.2012.02552.x
   PubMed Web of Science ®Google Scholar
• Wallace DK. Retinopathy of prematurity: anti-VEGF treatment for ROP: which drug and what dose? J AAPOS. 2016;20(6):476–478. doi:10.1016/j.jaapos.2016.08.013
   PubMed Web of Science ®Google Scholar
• Beck KD, Rahman EZ, Ells A, Mireskandari K, Berrocal AM, Harper CA. SAFER-ROP: updated protocol for anti-VEGF injections for retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina. 2020;51(7):402–406. doi:10.3928/23258160-20200702-05
   PubMed Web of Science ®Google Scholar
• Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153(2):327–333.e1. doi:10.1016/j.ajo.2011.07.005
   PubMed Web of Science ®Google Scholar
• Tran KD, Cernichiaro-Espinosa LA, Berrocal AM. Management of retinopathy of prematurity--use of anti-VEGF therapy. Asia Pac J Ophthalmol. 2018;7(1):56–62. doi:10.22608/APO.2017436
   PubMed Web of Science ®Google Scholar
• VanderVeen DK, Cataltepe SU. Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity. Semin Perinatol. 2019;43(6):375–380. doi:10.1053/j.semperi.2019.05.011
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals UK Limited. Lucentis (Ranibizumab): anti-neovasculisation agent; 2022. Availbale from: https://www.novartis.com/sg-en/sites/novartis_sg/files/Lucentis-Feb2022.SIN-app180522-pdf.pdf. Accessed February 2, 2023.
   Google Scholar
• Huang Q, Zhao P. Anti-vascular endothelial growth factor treatment for retinopathy of prematurity. Ann Eye Sci. 2017;2(7):47. doi:10.21037/aes.2017.02.06
   Google Scholar
• Cheng HC, Lee SM, Hsieh YT, Lin PK. Efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for stage 4 retinopathy of prematurity. Retina. 2015;35(4):660–666. doi:10.1097/IAE.0000000000000359
   PubMed Web of Science ®Google Scholar
• Stahl A, Krohne TU, Eter N, et al. Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr. 2018;172(3):278–286. doi:10.1001/jamapediatrics.2017.4838
   PubMed Web of Science ®Google Scholar
• Stahl A, Lepore D, Fielder A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019;394(10208):1551–1559. doi:10.1016/S0140-6736(19)31344-3
   PubMed Web of Science ®Google Scholar
• Marlow N, Stahl A, Lepore D, et al. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial. Lancet Child Adolesc Health. 2021;5(10):698–707. doi:10.1016/S2352-4642(21)00195-4
   PubMedGoogle Scholar
• Zehetner C, Kralinger MT and Modi YS, et al. (2015). Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Ophthalmol, 93(2), e154–e159. 10.1111/aos.12604
   PubMed Web of Science ®Google Scholar
• EYLEA® (aflibercept) Injection, for intravitreal use, Regeneron Pharmaceuticals, Inc; 2011. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125387s061lbl.pdf. Accessed 5 January 2023.
   Google Scholar
• Vedantham V. Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity. Indian J Ophthalmol. 2019;67(6):884–888. doi:10.4103/ijo.IJO_708_18
   PubMedGoogle Scholar
• Stahl A, Sukgen EA, Wu WC, et al. Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial. JAMA. 2022;328(4):348–359. doi:10.1001/jama.2022.10564
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine. Study to assess the efficacy, safety, and tolerability of intravitreal aflibercept compared to laser photocoagulation in patients with retinopathy of prematurity (BUTTERFLEYE); 2019. Availbale from: https://clinicaltrials.gov/ct2/show/NCT04101721. Accessed February 2, 2023.
   Google Scholar
• Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013;27(7):787–794. doi:10.1038/eye.2013.107
   PubMed Web of Science ®Google Scholar
• Eldweik L, Mantagos IS. Role of VEGF inhibition in the treatment of retinopathy of prematurity. Semin Ophthalmol. 2016;31(1–2):163–168. doi:10.3109/08820538.2015.1114847
   PubMed Web of Science ®Google Scholar
• Chandra P, Kumawat D, Tewari R, Azimeera S. Post-ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol. 2019;67(6):967–969. doi:10.4103/ijo.IJO_884_17
   PubMedGoogle Scholar
• Lepore D, Quinn GE, Molle F, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology. 2014;121(11):2212–2219. doi:10.1016/j.ophtha.2014.05.015
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Geloneck MM. Review of effects of anti-VEGF treatment on refractive error. Eye Brain. 2016;8:135–140. doi:10.2147/EB.S99306
   PubMed Web of Science ®Google Scholar
• Lien R, Yu MH, Hsu KH, et al. Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS One. 2016;11(1):e0148019. doi:10.1371/journal.pone.0148019
   PubMed Web of Science ®Google Scholar
• Morin J, Luu TM, Superstein R, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137(4):e20153218. doi:10.1542/peds.2015-3218
   PubMed Web of Science ®Google Scholar
• Azad R, Gilbert C, Gangwe AB, et al. Retinopathy of prematurity: how to prevent the third epidemics in developing countries. Asia Pac J Ophthalmol. 2020;9(5):440–448. doi:10.1097/APO.0000000000000313
   PubMed Web of Science ®Google Scholar
• Jalali S, Kesarwani S, Hussain A. Outcomes of a protocol-based management for zone 1 retinopathy of prematurity: the Indian twin cities ROP screening program report number 2. Am J Ophthalmol. 2011;151(4):719–724.e2. doi:10.1016/j.ajo.2010.10.007
   PubMed Web of Science ®Google Scholar
• Wu WC, Lien R, Liao PJ, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol. 2015;133(4):391–397. doi:10.1001/jamaophthalmol.2014.5373
   PubMed Web of Science ®Google Scholar
• Jalali S, Balakrishnan D, Zeynalova Z, Padhi TR, Rani PK. Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian twin cities retinopathy of prematurity screening database report number 5. Arch Dis Child Fetal Neonatal Ed. 2013;98(4):F327–F333. doi:10.1136/archdischild-2012-302365
   PubMed Web of Science ®Google Scholar
• Fidler M, Fleck BW, Stahl A, et al.; on behalf of the RAINBOW study group. Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial. Transl Vis Sci Tech. 2020;9(8):43. doi:10.1167/tvst.9.8.43
   PubMed Web of Science ®Google Scholar
• Stuart A. Current ROP therapies: how laser and anti-VEGF compare. Eye Net Mag. 2014. Availbale from: https://www.aao.org/eyenet/article/current-rop-therapies-how-laser-antivegf-compare. Accessed February 2, 2023.
   Google Scholar
• VanderVeen DK, Melia M, Yang MB, Hutchinson AK, Wilson LB, Lambert SR. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American academy of ophthalmology. Ophthalmology. 2017;124(5):619–633. doi:10.1016/j.ophtha.2016.12.025
   PubMed Web of Science ®Google Scholar
• Snyder LL, Garcia-Gonzalez JM, Shapiro MJ, Blair MP. Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2016;47(3):280–283. doi:10.3928/23258160-20160229-12
   PubMed Web of Science ®Google Scholar
• Hajrasouliha AR, Garcia-Gonzales JM, Shapiro MJ, Yoon H, Blair MP. Reactivation of retinopathy of prematurity three years after treatment with bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2017;48(3):255–259. doi:10.3928/23258160-20170301-10
   PubMed Web of Science ®Google Scholar
• Dudani AI, Dudani A, Dudani K. Commentary: antivascular endothelial growth factor and retinopathy of prematurity. Indian J Ophthalmol. 2019;67(6):969–970. doi:10.4103/ijo.IJO_1220_17
   PubMedGoogle Scholar
• Tasman W. Retinopathy of prematurity: do we still have a problem?: The Charles L. Schepens lecture. Arch Ophthalmol. 2011;129(8):1083–1086. doi:10.1001/archophthalmol.2011.192
   PubMedGoogle Scholar
• Wallace DK, Kraker RT, Freedman SF, et al. Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol. 2017;135(6):654–656. doi:10.1001/jamaophthalmol.2017.1055
   PubMed Web of Science ®Google Scholar
• Wallace DK, Dean TW, Hartnett ME, et al. A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments. Ophthalmology. 2018;125(12):1961–1966. doi:10.1016/j.ophtha.2018.05.001
   PubMed Web of Science ®Google Scholar
• Ells AL, Wesolosky JD, Ingram AD, Mitchell PC, Platt AS. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity. Can J Ophthalmol. 2017;52(5):468–474. PMID: 28985806. doi:10.1016/j.jcjo.2017.02.012
   PubMed Web of Science ®Google Scholar
• Wallace DK, Kraker RT, Freedman SF, et al. Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity. JAMA Ophthalmol. 2020;138(6):698–701. doi:10.1001/jamaophthalmol.2020.0334
   PubMed Web of Science ®Google Scholar
• Mills MD. Evaluating the Cryotherapy for Retinopathy of Prematurity Study (CRYO-ROP). Arch Ophthalmol. 2007;125(9):1276–1281. doi:10.1001/archopht.125.9.1276
   PubMed Web of Science ®Google Scholar
• Patel SN, Klufas MA. Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity. Eye Brain. 2019;11:25–35. doi:10.2147/EB.S189684
   PubMed Web of Science ®Google Scholar
• Tawse KL, Jeng-Miller KW, Baumal CR. Current practice patterns for treatment of retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina. 2016;47(5):491–495. doi:10.3928/23258160-20160419-16
   PubMed Web of Science ®Google Scholar
• Wang SD, Zhang GM; Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a meta-analysis. Int J Ophthalmol. 2020;13(5):806–815. doi:10.18240/ijo.2020.05.17
   PubMed Web of Science ®Google Scholar
• Linghu D, Cheng Y, Zhu X, et al. Comparison of intravitreal anti-VEGF agents with laser photocoagulation for retinopathy of prematurity of 1627 eyes in China. Front Med. 2022;9:911095. PMID: 35712119; PMCID: PMC9193577. doi:10.3389/fmed.2022.911095
   Web of Science ®Google Scholar
• Sen P, Agarwal AAK, Bhende P, Ganesan S. Treatment outcomes of combination of anti-vascular endothelial growth factor injection and laser photocoagulation in type 1 ROP and APROP. Int Ophthalmol. 2022;42(1):95–101. doi:10.1007/s10792-021-02004-8
   PubMed Web of Science ®Google Scholar
• Gotz-Więckowska A, Chmielarz-Czarnocińska A, Pawlak M, Gadzinowski J, Mazela J. Ranibizumab after laser photocoagulation failure in retinopathy of prematurity (ROP) treatment. Sci Rep. 2017;7(1):11894. doi:10.1038/s41598-017-12264-z
   PubMedGoogle Scholar
• Castellanos MAM, Schwartz S, Leal R, Chan RVP, Quiroz-Mercado H. Pain assessment in premature infants treated with intravitreal antiangiogenic therapy for retinopathy of prematurity under topical anesthesia. Graefes Arch Clin Exp Ophthalmol. 2013;251(2):491–494. doi:10.1007/s00417-012-2060-2
   PubMed Web of Science ®Google Scholar
• Tokgöz O, Sahin A, Tüfek A, et al. Inhalation anesthesia with sevoflurane during intravitreal bevacizumab injection in infants with retinopathy of prematurity. BioMed Res Int. 2013;2013:435387. doi:10.1155/2013/435387
   PubMed Web of Science ®Google Scholar
• Vitreo Retinal Society, India. Guidelines for intravitreal injection of avastin (bevacizumab); 2017. Availbale from: https://vrsi.in/wp-content/uploads/2018/02/Avastin_Guidlines_Book.pdf. Accessed February 2, 2023.
   Google Scholar
• Kara C, Hekimoğlu E, Petriçli İS, Akıl H. Intravitreal bevacizumab as rescue therapy following treatment failure with laser photocoagulation in retinopathy of prematurity. J Curr Ophthalmol. 2018;30(1):80–84. doi:10.1016/j.joco.2017.08.007
   PubMed Web of Science ®Google Scholar
• Cheng Y, Liu TG, Li WY, Zhao MW, Liang JH. Fluorescein angiography of retinal vascular involution after intravitreal injection of ranibizumab for retinopathy of prematurity. Int J Ophthalmol. 2019;12(1):79–82. doi:10.18240/ijo.2019.01.12
   PubMed Web of Science ®Google Scholar
• Al Rasheed R, Adhi MI, Alowedi SA, Albdah B, Aldebasi T, Hazzazi MA. Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography. Int J Retina Vitr. 2022;8(1):53. doi:10.1186/s40942-022-00402-3
   PubMedGoogle Scholar
• Sternfeld A, Rahmani S, Rossen JL, et al. Long-term retinal vasculature abnormalities following intravitreal bevacizumab for retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2022;260:1915–1921. doi:10.1007/s00417-021-05499-0
   PubMed Web of Science ®Google Scholar
• Day S, Rainey AM, Harper CA III. Incomplete retinal vascularization after ranibizumab treatment of retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina. 2017;48(1):75–78. doi:10.3928/23258160-20161219-11
   PubMed Web of Science ®Google Scholar
• Lepore D, Quinn GE, Molle F, et al. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology. 2018;125(2):218–226. doi:10.1016/j.ophtha.2017.08.005
   PubMed Web of Science ®Google Scholar
• Isaac M, Tehrani N, Mireskandari K. Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up. Eye. 2016;30(3):333–341. doi:10.1038/eye.2015.289
   PubMed Web of Science ®Google Scholar